Magnetic pulses aim to lift depression in bipolar II
NCT ID NCT05849402
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether a rapid form of brain stimulation, called accelerated intermittent theta-burst stimulation (aiTBS), can relieve depression in people with bipolar II disorder whose depression has not responded to other treatments. Participants receive either real or sham (inactive) stimulation to the left prefrontal cortex over five days. The goal is to see if aiTBS can safely reduce depressive symptoms without the need for medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
accelerated intermittent theta-burst transcranial magnetic stimulation (aiTBS)
What this could lead to
If effective, aiTBS could offer a non-drug option for people with bipolar II depression who haven't responded to standard treatments.
What could go wrong
This is a small, early-stage trial with 60 participants, and the sham comparison means some may not benefit. Brain stimulation can cause discomfort or rare side effects like seizure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT RESISTANT DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
Palo Alto, California, 94305, United States